| Ytd | -24.59% | |
| 1y | -65.64% |
| Open | 5.08 | Prev Close | 4.92 | Low | 4.90 | High | 5.08 | Mkt Cap | 39.74M |
| Vol | 16.49K | Avg Vol | 28.25K | EPS | -17.03 | P/E | N/A | Forward P/E | -0.45 |
| Beta | 0.54 | Short Ratio | 9.07 | Inst. Own | 14.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 5.20 | 200-d Avg | 7.90 | 1yr Est | 9.00 |
PAVM News
Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the pr
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
On Friday, PAVmed (NASDAQ:PAVM) discussed second-quarter financial results during its earnings call.
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.27) per share which beat the analyst consensus
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physi
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory be
PAVmed (NASDAQ: PAVM - Get Free Report) and Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) are b
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage cr
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Compa
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (Nasd
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the pr
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Esti
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(1.17) per share which missed the analyst consens
Veris Health progressed commercial expansion and advanced implantable physiological monitor developm
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $4
PAVmed (PAVM) doesn't possess the right combination of the two key ingredients for a likely earnings
Conference Call and Webcast at 8:30 AM ET NEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq
Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ -- Lucid Diagnostic
NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Com
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage
NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Com
PAVmed Inc. (NASDAQ: PAVM - Get Free Report)'s stock price crossed below its 50-day moving average d
NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Com
PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diag
PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage,
PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-sta
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the pr
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.02) per share which beat the analyst consensus
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the pr